MYCN can down-regulate the epigenetically controlled miR-335, a tumour suppressor miRNA, leading to over-expression in target genes of the Transforming Growth Factor beta (TGF-β) non-canonical pathway, inhibiting both the migration and invasion of NB cells [42]. The gene discussed is MYCN; the disease is neuroblastoma.